Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status approved; investigational
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 0069-0145; 54893-0032; 68554-0088; 63539-026; 82920-028; 0069-0151; 65344-0033; 63539-044; 54893-0043
UNII C9LVQ0YUXG
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary haemorrhage22.12.01.009; 24.07.01.0160.000168%
Pulmonary infarction24.04.09.001; 22.06.02.0020.000112%Not Available
Pulmonary thrombosis24.01.06.002; 22.06.02.0030.000492%Not Available
Rash23.03.13.001--Not Available
Rash papular23.03.13.0170.000571%Not Available
Rash pruritic23.03.13.0300.001936%Not Available
Rectal haemorrhage07.12.03.001; 24.07.02.018--
Renal cancer20.01.04.002; 16.08.02.0010.026695%Not Available
Renal disorder20.01.02.0020.001757%Not Available
Renal failure20.01.03.0050.002261%Not Available
Renal haemorrhage24.07.07.002; 20.01.02.013; 12.01.05.0040.000336%
Renal pain20.02.03.0030.000604%Not Available
Respiration abnormal22.02.01.0410.000381%Not Available
Retching07.01.07.0020.000739%Not Available
Retinal artery occlusion24.01.07.003; 06.10.01.0050.000112%Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.0010.000224%Not Available
Retinal vascular disorder24.03.07.002; 06.10.01.0020.000112%
Retinal vascular occlusion24.04.10.004; 06.10.01.008--Not Available
Retinal vein occlusion24.01.07.006; 06.10.01.010--Not Available
Rhinitis allergic10.01.04.003; 22.04.04.0030.000571%
Rhinorrhoea22.12.03.0210.002563%
Salivary hypersecretion07.06.01.0090.000168%Not Available
Sciatica17.10.03.001; 15.10.01.0010.000246%Not Available
Scrotal ulcer23.07.03.007; 21.12.02.0070.000246%Not Available
Second primary malignancy16.16.01.0140.002406%
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.0140.000112%Not Available
Sinus headache22.12.03.022; 17.14.01.0020.000437%
Skin atrophy23.01.05.0010.000492%
Skin discolouration23.03.03.0050.002071%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 17 Pages